In an associated Commentary titled Thyroid Cancer Risk with GLP-1 Receptor Agonists: Evidence, Knowledge Gaps, and the Path Forward, Juan Brito, MD , from the Mayo Clinic, and coauthors, stated the following: this study stands out for its large scale and robust methodology
Fasting and PP glucose, insulin, HbA1c, GSH, oxidized glutathione (GSSG), and 8-hydroxy-2-deoxy guanosine (8-OHdG) were measured upon recruitment and after three and six months of supplementation
A.GaoH.LuoL.et al (2023)
Consider GlyNAC
Our unique approach to the application of Lumi Eyes sets us apart, allowing us to maximize the benefits of this innovative treatment
Forest plot of GLP-1 receptor agonists versus comparators on the risk of Pulmonary embolism